target tumors and activate anti-tumor
immune responses.
Scientific Capabilities Driving Translational Innovation
Our Work
Current Research Initiatives & Core Innovation Pillars
HSV Vaccine & Viral Immunotherapy Platform
IBG develops engineered herpes simplex virus (HSV) platforms designed for next-generation vaccines & oncolytic immunotherapy. Our proprietary VC2/ViraVac™ backbone is a live-attenuated HSV-1 vector optimized for safety while retaining strong immune activation. The platform is being explored for prophylactic vaccination, therapeutic cancer immunotherapy, & tumor-targeted viral delivery strategies. Our work integrates molecular virology, immune biology, and translational design to create HSV vectors that activate systemic immune responses while minimizing neurovirulence. Preclinical models demonstrate robust immune infiltration, reduced metastatic burden, and durable anti-tumor signaling.
AI-Driven Phytochemical & Target Discovery
IBG applies artificial intelligence and machine-learning workflows to identify biologically active phytochemicals and therapeutic targets across oncology and inflammatory disease. Our discovery engine integrates literature mining, pathway modeling, omics interpretation, and chemical prioritization to accelerate hypothesis generation and candidate selection. This platform supports the development of proprietary natural-compound formulations, target discovery pipelines, and collaborative R&D programs. AI-guided discovery allows IBG to bridge computational biology with experimental validation for scalable translational innovation.
WHO WE ARE
IOS Biomedical Group (IBG) is a translational biotechnology company building platform technologies at the intersection of virology, immunotherapy, and AI-enabled discovery. We focus on engineered viral systems and computational intelligence to accelerate the development of next-generation biomedical solutions. Our work is rooted in deep molecular science and designed for real-world translation. IBG operates as a platform company - not a single-product startup - developing adaptable technologies that support vaccines, tumor-targeted viral immunotherapy, and precision discovery pipelines. We combine laboratory research, data-driven modeling, and milestone-driven execution to bridge scientific innovation with scalable therapeutic development. IBG is structured to collaborate with academic institutions, federal research programs, and industry partners to move promising science into translational pipelines.
WHAT WE DO
IBG develops integrated discovery platforms that enable new approaches to vaccines, cancer immunotherapy, and biologically guided compound discovery. Our core HSV platform is engineered for enhanced safety and immune activation, supporting both prophylactic vaccine strategies and oncolytic viral immunotherapy. These vectors are designed to trigger systemic immune responses, recruit tumor-targeting immune cells, and support adaptable therapeutic design across disease areas. In parallel, our AI-driven discovery engine identifies phytochemicals and therapeutic targets through multi-omics integration, pathway analysis, and large-scale literature intelligence. This computational platform accelerates candidate prioritization and supports the development of natural compound formulations and collaborative research programs. Together, these systems form a modular innovation framework designed to expand translational biomedical capabilities.
Publication Highlights
Our Scientists
Konstantin “Gus” Kousoulas, PHD
CEO and Founder
Effie Kousoulas
Co-Founder
